Article (Scientific journals)
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov, U.; Mantzaris, G. J.; Katsanos, K. H. et al.
2011In Alimentary Pharmacology and Therapeutics, 33 (3), p. 349-57
Peer Reviewed verified by ORBi
 

Files


Full Text
2010-The efficacy of shortening the dosing interval...Crohn's patients...maintenance doses of Infliximab-AP&T-PostPA.pdf
Author postprint (706.83 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Antibodies, Monoclonal/administration & dosage; Crohn Disease/drug therapy; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents/administration & dosage; Humans; Male; Retrospective Studies; Statistics as Topic; Time Factors; Treatment Outcome; Young Adult
Abstract :
[en] Background Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks. Aim We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling. Methods This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). Results Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.). Conclusion In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Kopylov, U.
Mantzaris, G. J.
Katsanos, K. H.
Reenaers, Catherine ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Ellul, P.
Rahier, Jean-François
Israeli, E.
Lakatos, P. L.
Fiorino, G.
Cesarini, M.
Tsianos, E. V.
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Ben-Horin, S.
More authors (3 more) Less
Language :
English
Title :
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Publication date :
2011
Journal title :
Alimentary Pharmacology and Therapeutics
ISSN :
0269-2813
eISSN :
1365-2036
Publisher :
Blackwell Publishing, Oxford, United Kingdom
Volume :
33
Issue :
3
Pages :
349-57
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2010 Blackwell Publishing Ltd.
Available on ORBi :
since 01 March 2011

Statistics


Number of views
126 (9 by ULiège)
Number of downloads
195 (2 by ULiège)

Scopus citations®
 
80
Scopus citations®
without self-citations
59
OpenCitations
 
70

Bibliography


Similar publications



Contact ORBi